OABI Stock Overview
A biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
OmniAb, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.93 |
| 52 Week High | US$5.06 |
| 52 Week Low | US$1.81 |
| Beta | 0.80 |
| 1 Month Change | -41.69% |
| 3 Month Change | -39.50% |
| 1 Year Change | -61.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.41% |
Recent News & Updates
Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities
Mar 29 Strong growth in partners and programs suggests robust future milestone and royalty revenues as technologies attract significant opportunities.OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 15
Recent updates
Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities
Mar 29 Strong growth in partners and programs suggests robust future milestone and royalty revenues as technologies attract significant opportunities.OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 15Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?
Sep 14Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?
Jul 15The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Mar 26Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
Feb 28OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Jan 15Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
Nov 11Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
Aug 13OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
May 14Shareholder Returns
| OABI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -7.7% | 1.2% | 5.8% |
| 1Y | -61.0% | -26.6% | 4.8% |
Return vs Industry: OABI underperformed the US Life Sciences industry which returned -26.6% over the past year.
Return vs Market: OABI underperformed the US Market which returned 4.8% over the past year.
Price Volatility
| OABI volatility | |
|---|---|
| OABI Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 10.5% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: OABI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OABI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 114 | Matt Foehr | www.omniab.com |
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics.
OmniAb, Inc. Fundamentals Summary
| OABI fundamental statistics | |
|---|---|
| Market cap | US$235.72m |
| Earnings (TTM) | -US$62.03m |
| Revenue (TTM) | US$26.39m |
8.9x
P/S Ratio-3.8x
P/E RatioIs OABI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OABI income statement (TTM) | |
|---|---|
| Revenue | US$26.39m |
| Cost of Revenue | US$0 |
| Gross Profit | US$26.39m |
| Other Expenses | US$88.42m |
| Earnings | -US$62.03m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | 100.00% |
| Net Profit Margin | -235.05% |
| Debt/Equity Ratio | 0% |
How did OABI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 10:11 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OmniAb, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Wasserman | Benchmark Company |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Tiago Fauth | Credit Suisse |